Vertex Pharmaceuticals Incorporated has announced that Ludovic Fenaux has been appointed Senior Vice President, International Commercial Operations with responsibility for commercial activities outside of the U.S. and Canada, which includes overseeing offices and operations across Europe, Australia and Latin America.
Mr. Fenaux started his role with Vertex on August 20 and reports to Stuart Arbuckle, Executive Vice President and Chief Commercial Officer. Mr. Fenaux is based at the International headquarters in London and succeeds Simon Bedson, who is retiring after seven years as Vertex’s Senior Vice President and General Manager, International Commercial Operations and nearly 30 years in the pharmaceutical industry.
“I am excited to Join Vertex at a time when the company is not only pursuing medicines that treat cystic fibrosis but also investing in other serious diseases.”
Since joining in 2011, Mr. Bedson has successfully led Vertex’s global expansion outside of North America, including the establishment of the company’s international headquarters and commercial offices and operations across Europe, Australia and Latin America.
Mr. Fenaux joins Vertex with more than two decades of pharmaceutical industry experience, most recently at Bristol-Myers Squibb where he held the position of Senior Vice President, Head of Intercontinental Region.
In addition to Mr. Fenaux’s leadership position at Bristol-Myers Squibb as Senior Vice President, Head of Intercontinental Region, Ludovic was Head of U.S. Specialty Care, Head of U.S. Commercial Virology and Transplant, Vice President and General Manager Benelux and Vice President, Global Commercialisation Oncology.
Stuart Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex said, “I would like to thank Simon for his leadership, dedication and enormous contribution to Vertex. He has played a pivotal role in the growth of our company internationally and we wish him all the best in retirement.
“I am also thrilled to welcome Ludovic to Vertex and our global commercial leadership team. Ludovic brings the leadership skills and functional and geographic experience our growing international organisation needs as we become a leading global biotechnology company.”
Mr. Fenaux said, “I am excited to be joining Vertex at a time when the company is not only pursuing medicines that treat cystic fibrosis but also investing in other serious diseases, tackling the biggest challenges in medicine. I look forward to being part of an industry leader, driven by an understanding of human biology, to progress scientific innovations that address the underlying cause of disease.”